- Home
- CHRW vs NBIX Comparison
CHRW vs NBIX Comparison
Compare CHRW & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHRW | NBIX |
|---|---|---|
| Founded | 1905 | 1992 |
| Country | United States | United States |
| Employees | 13781 | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6B | 14.4B |
| IPO Year | 1997 | 1996 |
Fundamental Metrics
Financial Performance| Metric | CHRW | NBIX |
|---|---|---|
| Price | $156.47 | $155.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 19 |
| Target Price | $137.86 | ★ $173.79 |
| AVG Volume (30 Days) | ★ 1.4M | 969.9K |
| Earning Date | 10-29-2025 | 10-28-2025 |
| Dividend Yield | ★ 1.60% | N/A |
| EPS Growth | ★ 70.68 | 12.44 |
| EPS | ★ 4.94 | 4.19 |
| Revenue | ★ $16,504,785,000.00 | $2,682,700,000.00 |
| Revenue This Year | N/A | $23.76 |
| Revenue Next Year | $3.08 | $18.01 |
| P/E Ratio | ★ $31.86 | $37.10 |
| Revenue Growth | N/A | ★ 19.61 |
| 52 Week Low | $84.68 | $84.23 |
| 52 Week High | $162.79 | $157.67 |
Technical Indicators
Market Signals| Indicator | CHRW | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 62.89 | 64.81 |
| Support Level | $158.37 | $150.26 |
| Resistance Level | $162.79 | $154.35 |
| Average True Range (ATR) | 3.24 | 4.16 |
| MACD | -0.36 | 1.07 |
| Stochastic Oscillator | 60.86 | 93.25 |
Price Performance
Historical ComparisonAbout CHRW C.H. Robinson Worldwide Inc.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (about 60% of net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm operates a large air and ocean forwarding division (30%), which has grown organically and via tuck-in acquisitions over the years. The remainder of revenue consists of transportation management services and a legacy produce-sourcing operation.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.